← SynDRA
CABOZANTINIB
SynDRA canonical compound SYN0031584 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx |
| Primary target(s) | TEK |
| Mechanism of action | RET tyrosine kinase inhibitor |
| Indication | medullary thyroid cancer (MTC) |
| Disease area | oncology |
All known targets
- KDR
- MET
- RET
- TEK
- FLT3
- KIT
- SRC
- RIPK3
- RIPK2
- PTK6
- PIP4K2C
- NTRK1
Mechanisms of action (all sources)
- VEGFR inhibitor
- RET tyrosine kinase inhibitor
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- RET INHIBITOR
- KIT INHIBITOR
- FLT3 INHIBITOR
- TEK INHIBITOR
Drug classes
- Protein Kinase Inhibitors
- Kinase Inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- cabozantinib malate
- cabozantinib (S)-malate
- cometriq
- XL184
- cabozantinib S-malate
- cabometyx
- BMS-907351
- BMS-907351 FREE BASE
- Cabometyx
- CABOZANTINIB (BMS-907351)
- Cabozantinib s-malate
- CABOZANTINIBCT-XL184COMETRIQXL184C3627
- Cometriq
- XL-184
- XL-184 FREE BASE
- XL184 FREE BASE
- XL184,BMS-907351
- XL 184
- BMS 907351
- XL-184 free base
- Cabozantinib (XL184, BMS-907351)
- Cabozantinib [USAN]
- CHEBI:72317
- BMS907351
- 1C39JW444G
- MFCD20926324
- Cabozantinib (USAN)
- N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE
- XL-184 (Cabozantinib,BMS907351)
- Cabometyx (TN)
- Cometriq (TN)
- 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
- 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-
- N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
- XL184 cpd
- Cabozantinib [USAN:INN]
- Carbozantinib
Look up CABOZANTINIB in the interactive SynDRA portal →